Cerebral Infarction Clinical Trial
The investigators team had found that the presence of dynamic changes of Clopidogrel resistance are not associated with genetic factors. Currently, study on moderate doses of statins and dynamic Clopidogrel resistance has not been reported, therefore this study will observe 160 cases of open prospective secondary prevention in patients with cerebral infarction. Excluded: those patients occurs Clopidogrel resistance because of slow metabolism caused by cytochrome P450 isoenzyme 2C19(CYP2C19, and then observed the impact of the cytochrome P450 isoenzyme 3A4 (CYP3A4)-metabolized and non-cytochrome P450 isoenzyme 3A4 (CYP3A4)—metabolized statins dynamically on Clopidogrel resistance in the next 9 months, adverse events will be recorded, the metabolite of clopidogrel(H4 )and the polymorphism of cytochrome P450 isoenzyme 2C19 (CYP2C19)/cytochrome P450 isoenzyme 3A4 (CYP3A4)/ cytochrome P450 isoenzyme 2C9(CYP2C9)will be detected. Expected Result: the patients use the cytochrome P450 isoenzyme 3A4(CYP3A4)-metabolized statins will result in dynamic Clopidogrel resistance easily ,H4 levels will decline, and Clopidogrel resistance is not related to the polymorphism of cytochrome P450 isoenzyme 3A4 (CYP3A4).
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT00684515 -
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
|
Phase 2 | |
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Terminated |
NCT01684462 -
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00386191 -
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
|
Phase 4 | |
Completed |
NCT00004734 -
Vitamin Therapy for Prevention of Stroke
|
Phase 3 | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Completed |
NCT02248233 -
Nimodipine for Treating Acute Massive Cerebral Infarction
|
Phase 4 | |
Completed |
NCT02963545 -
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
|
N/A | |
Completed |
NCT02511249 -
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
|
N/A | |
Completed |
NCT02101606 -
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT01500421 -
Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)
|
Phase 2 | |
Completed |
NCT00829361 -
Stroke Telemedicine for Arizona Rural Residents Trial
|
N/A | |
Recruiting |
NCT01003470 -
Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study
|
Phase 2 | |
Terminated |
NCT00331890 -
ICTUS Study: International Citicoline Trial on Acute Stroke
|
Phase 3 | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03741400 -
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
|
N/A |